Peapod Lane Capital LLC Invests $311,000 in NextCure, Inc. (NASDAQ:NXTC)

Peapod Lane Capital LLC purchased a new stake in NextCure, Inc. (NASDAQ:NXTC) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 403,698 shares of the company’s stock, valued at approximately $311,000. Peapod Lane Capital LLC owned about 1.44% of NextCure as of its most recent filing with the Securities and Exchange Commission.

Separately, Geode Capital Management LLC boosted its holdings in shares of NextCure by 14.2% during the third quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock worth $307,000 after acquiring an additional 27,812 shares during the period. Institutional investors and hedge funds own 42.65% of the company’s stock.

NextCure Price Performance

NXTC opened at $0.70 on Thursday. The stock has a fifty day moving average of $0.87 and a 200-day moving average of $1.22. NextCure, Inc. has a fifty-two week low of $0.67 and a fifty-two week high of $2.57.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their target price on NextCure from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Monday, November 11th.

NextCure Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.